Patient Support Services Contact Us
Expanding Our Mission to Immuno-oncology
More choice without compromise

Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences’ anti-PD-1 antibody.

Learn More

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

Learn More

Coherus teams up with biomanufacturing partner KBI Biopharma and JSR Life Sciences in support of Marshall Fire disaster recovery in Boulder County, Colo.

Coherus BioSciences, Inc. is proud to team up with our UDENYCA® (pegfilgrastim-cbqv) biomanufacturing partner KBI Biopharma and their parent company JSR Life Sciences to donate $40,000 to the Boulder County Wildfire Fund to support the heroic first responders who helped save the community from the recent Marshall Fire.

Community Foundation Boulder County launched the Fund and will work closely with government and nonprofit partners to coordinate, align resources and fill gaps to support those impacted by the wildfire. KBI has two facilities in the areas most directly impacted, and many KBI employees from the Boulder site were personally affected, ranging from complete loss of their homes and smoke damage to evacuations and neighborhood disruption. The UDENYCA® supply chain was not disrupted.

To date, Community Foundation Boulder County has distributed more than $5 million in financial assistance to thousands of people whose homes have been destroyed or damaged or were evacuated.

Learn more about the Marshall Fire disaster recovery efforts

Latest News

Coherus BioSciences Announces New Employment Inducement Grants

Learn More

Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors

Learn More

Coherus BioSciences Management to Present at Upcoming Investor Conferences

Learn More

Coherus issues white paper supporting “Securing America’s Medicines & Supply”

View Now